Not medical advice. FOXO4-DRI is sold for research. This guide does not recommend dosing, diagnosis, or therapy.
FOXO4-DRI is listed in our catalogue under “Metabolic / Longevity.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.
FOXO4-DRI is a D-retro-inverso senolytic peptide that disrupts the FOXO4-p53 nuclear interaction to selectively induce apoptosis in senescent cells.
Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.
“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.
Researchers study these compounds for mitochondrial function, nutrient sensing, and cellular energy stress responses -often in ageing or metabolic disease models.
Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.
Storage: Lyophilised: -20 °C long-term. 2–8 °C for active use. - see our storage guide for best practices on temperature, light, and shelf life.
Typical research dosing discussion (literature-style): 5–10 mg subcutaneous injection · 3 times weekly for 3–4 weeks per cycle, with 4–8 week rest periods · No formal human pharmacokinetic data published. D-retro-inverso configuration significantly extends in vivo stability versus L-peptide equivalents. In preclinical studies, FOXO4-DRI was dissolved in PBS at 5 mg/mL and administered intraperitoneally. The large molecular weight (5358.2 Da) limits oral bioavailability; parenteral administration required. Cleara Biotech is advancing clinical development of FOXO4-p53 interaction modulators.
For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.
What is FOXO4-DRI in plain language?
FOXO4-DRI is a research peptide we catalogue under “Metabolic / Longevity.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.
Does this page give medical advice or dosing instructions for FOXO4-DRI?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.
Where can I see purity, variants, and pricing for FOXO4-DRI?
Use the “View product” button to open the canonical shop listing for FOXO4-DRI, where specifications and research SKU details are shown.
What about online case reports, before-and-after stories, or forum “logs” for FOXO4-DRI?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.
Open the shop listing for variants, purity notes, and research SKU details.
View productAlso known as: FOXO4-DRI, Proxofim, FOXO4 D-Retro-Inverso Peptide, FOXO4-p53 Interaction Blocker, Senolytic Peptide FOXO4-DRI, ES2